Literature DB >> 14755819

TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent?

Andrew J Carter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14755819     DOI： 10.1002/ccd.10764

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN： 1522-1946            Impact factor:   2.692


× No keyword cloud information.
  9 in total

Review 1.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

2.  Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.

Authors:  William M Wolf; Helen A Vlachos; Oscar C Marroquin; Joon S Lee; Conrad Smith; William D Anderson; John T Schindler; Elizabeth M Holper; J Dawn Abbott; David O Williams; Warren K Laskey; Kevin E Kip; Sheryl F Kelsey; Suresh R Mulukutla
Journal:  Circ Cardiovasc Interv       Date:  2010-01-26       Impact factor: 6.546

3.  DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects.

Authors:  Gang Zhang; Samuel Kim; Xiaohuan Gu; Shan Ping Yu; Ling Wei
Journal:  Neurosci Bull       Date:  2019-12-05       Impact factor: 5.203

4.  A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.

Authors:  Carolyn L Buller; Robert D Loberg; Ming-Hui Fan; Qihong Zhu; James L Park; Eileen Vesely; Ken Inoki; Kun-Liang Guan; Frank C Brosius
Journal:  Am J Physiol Cell Physiol       Date:  2008-07-23       Impact factor: 4.249

5.  Type 2 diabetes and coronary heart disease: focus on myocardial infarction.

Authors:  Rodrigo M Lago; Richard W Nesto
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

6.  A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease.

Authors:  Johan Bennett; Christophe Dubois
Journal:  Biologics       Date:  2013-06-19

Review 7.  Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.

Authors:  Christoph Stettler; Sabin Allemann; Simon Wandel; Adnan Kastrati; Marie Claude Morice; Albert Schömig; Matthias E Pfisterer; Gregg W Stone; Martin B Leon; José Suárez de Lezo; Jean-Jacques Goy; Seung-Jung Park; Manel Sabaté; Maarten J Suttorp; Henning Kelbaek; Christian Spaulding; Maurizio Menichelli; Paul Vermeersch; Maurits T Dirksen; Pavel Cervinka; Marco De Carlo; Andrejs Erglis; Tania Chechi; Paolo Ortolani; Martin J Schalij; Peter Diem; Bernhard Meier; Stephan Windecker; Peter Jüni
Journal:  BMJ       Date:  2008-08-29

Review 8.  Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V).

Authors:  Imad Sheiban; Gianluca Villata; Mario Bollati; Dario Sillano; Marzia Lotrionte; Giuseppe Biondi-Zoccai
Journal:  Vasc Health Risk Manag       Date:  2008

Review 9.  Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes.

Authors:  Vasileios F Panoulas; Ioannis Mastoris; Klio Konstantinou; Maurizio Tespili; Alfonso Ielasi
Journal:  Med Devices (Auckl)       Date:  2015-07-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.